OGD generic drug review times improving without user fees, Barr CEO Downey tells FDLI.
Executive Summary
OFFICE OF GENERIC DRUGS APPROVAL TIMES IMPROVING WITHOUT USER FEES, BARR Labs CEO Bruce Downey stressed to the Food & Drug Law Institute annual meeting in Washington, D.C. Dec. 10. "Left to its own devices, [OGD] has done an excellent job and review times have gone down," Downey said. "I would note two things about that. It is without user fees, and it was with a reduced staff," he asserted.